Bio Protech, Inc.

As of December 31, 2025, Bio Protech, Inc. carries a market capitalization of 8.15B, placing it among publicly traded companies globally. Its enterprise value stands at 24.48B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, Bio Protech, Inc. has 16.33M shares outstanding.

As of December 31, 2025, Bio Protech, Inc. trades at a trailing price-to-earnings ratio of 77.38. The price-to-sales ratio is 0.24, and the price-to-book ratio stands at -0.70.

As of December 31, 2025, Bio Protech, Inc. trades at an EV/EBITDA multiple of 6.74 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.72 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 10.88 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 24.48B versus a market cap of 8.15B, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2025, Bio Protech, Inc. maintains a current ratio of 0.57, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -173.51, indicating conservative leverage, while an interest coverage ratio of 1.05 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2025. Return on invested capital (ROIC) is negative at -10.69, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 0.34, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is negative at -13.30, pointing to unprofitable operations over the period. The company generates approximately 290.01M in revenue per employee across its workforce of 118.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.15 indicates how many times Bio Protech, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended December 31, 2025, Bio Protech, Inc. recorded 16.49M in income tax expense. That works out to an effective tax rate of 138.67, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 11.90M, leaving 105.27M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Bio Protech, Inc.'s stock has declined approximately 8.89% over the past 52 weeks. The 50-day moving average sits at 389.66, while the 200-day moving average is 412.85.

Over the twelve months ended December 31, 2025, Bio Protech, Inc. generated 34.22B in revenue and converted that into 105.27M in net income, yielding earnings per share of -0.21. EBITDA reached 3.63B, while operating income came in at 2.65B.

As of December 31, 2025, Bio Protech, Inc. holds 3.45B in cash and equivalents against 19.23B in total debt, resulting in a net debt position of 14.92B. Total book value stands at -11.63B, with working capital of -14.97B providing operational flexibility.

Bio Protech, Inc. produced 1.69B in operating cash flow over the twelve months ended December 31, 2025. After subtracting -621.41M in capital expenditures, free cash flow totaled 1.07B - equivalent to 65.76 per share.

Over the twelve months ended December 31, 2025, Bio Protech, Inc. posted a gross margin of 32.38, reflecting its pricing power and cost economics. The operating margin of 7.74 and net profit margin of 0.31 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2025. Free cash flow yield stands at 9.90, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 12.53, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Bio Protech, Inc. shareholders.

As of December 31, 2025, Bio Protech, Inc. has an Altman Z-Score of -0.53, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.